{"totalCount":5,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07148414","orgStudyIdInfo":{"id":"SPY002-072-201"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of SPY072 in Rheumatic Disease","officialTitle":"Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease","acronym":"SKYWAY-RD"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-08-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-03-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-08-21","studyFirstSubmitQcDate":"2025-08-21","studyFirstPostDateStruct":{"date":"2025-08-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-01","lastUpdatePostDateStruct":{"date":"2026-02-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).","detailedDescription":"The basket study comprises of substudies in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatric arthritis (PsA) as follows:\n\n* RA substudy: Moderately to severely active RA despite treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic disease modifying anti-rheumatic drugs (bDMARDs), or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs)\n* axSpA substudy: Moderately to severely active axSpA despite treatment with non-steroidal anti-inflammatory drugs (NSAIDS), bDMARDs, or tsDMARDs\n* PsA substudy: Moderately to severely active PsA despite treatment with NSAIDs, csDMARDs, bDMARDs, or tsDMARDs"},"conditionsModule":{"conditions":["Rheumatoid Arthritis","Psoriatic Arthritis","Axial Spondyloarthritis","Rheumatic Diseases","Rheumatic Joint Disease","PsA (Psoriatic Arthritis)","AxSpA","Rheumatologic Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":285,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Rheumatoid Arthritis, Dose Regimen 1","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 1 of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Rheumatoid Arthritis, Dose Regimen 2","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 2 of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Psoriatic Arthritis","type":"EXPERIMENTAL","description":"Participants will receive double-blind dose of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Axial Spondyloarthritis","type":"EXPERIMENTAL","description":"Participants will receive double-blind dose of SPY072","interventionNames":["Drug: SPY002-072"]},{"label":"Rhematoid Arthritis Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Drug: Placebo"]},{"label":"Psoriatic Arthritis Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Drug: Placebo"]},{"label":"Axial Spondyloarthritis Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY002-072","description":"Experimental","armGroupLabels":["Axial Spondyloarthritis","Psoriatic Arthritis","Rheumatoid Arthritis, Dose Regimen 1","Rheumatoid Arthritis, Dose Regimen 2"],"otherNames":["SPY072"]},{"type":"DRUG","name":"Placebo","description":"Matching Placebo","armGroupLabels":["Axial Spondyloarthritis Placebo","Psoriatic Arthritis Placebo","Rhematoid Arthritis Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)","description":"The score is calculated based on the number of tender and swollen joints out of 28 assessed (TJC28 and SJC28), a measure of inflammation in the blood (c-reactive protein, CRP), and the subject's overall assessment of their health (patient global assessment). Scores range from 0-10. Higher scores indicate greater disease activity.","timeFrame":"Week 12"},{"measure":"Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS)","description":"The score combines 5 disease activity variables (back pain, duration of morning stiffness, patient global assessment of disease activity, peripheral pain/swelling and measure of inflammation) to measure disease activity. Lowest score is 0.6 and increases as disease worsens. Higher scores indicate greater disease activity.","timeFrame":"Week 16"},{"measure":"Psoriatic Arthritis: Proportion of participants who achieve an American College of Rheumatology 20 Response Criteria (ACR20) response","description":"The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts (TJC and SJC), and at least 20% improvement in 3 out of 5 other disease activity measures (patient global assessment, physician global assessment, patient pain assessment, health assessment questionnaire, and measure of inflammation) will be assessed.","timeFrame":"Week 16"}],"secondaryOutcomes":[{"measure":"Rheumatoid Arthritis: Proportion of participants who achieve an ACR20 response","description":"The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts, and at least 20% improvement in 3 out of 5 other disease activity measures will be assessed.","timeFrame":"Week 12"},{"measure":"Axial Spondyloarthritis: Proportion of participants who achieve an Assessment of Spondyloarthritis International Society (40% improvement) (ASAS40) response","description":"The proportion of subjects who achieve at least 40% improvement in at least 3 out of 4 key domains related to disease severity (patient global assessment of disease activity, back pain, physical function, inflammation) while not experiencing worsening in the remain domain will be assessed.","timeFrame":"Week 16"},{"measure":"Psoriatic Arthritis: Change from baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)","description":"The sum of 5 key disease variables (tender joint count, swollen joint count, patient pain assessment, patient global assessment of disease activity, and C-reactive protein) will be assessed. Scores range from 0.1 to 86. Higher score indicates higher disease activity.","timeFrame":"Week 16"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor rheumatoid arthritis:\n\n* Moderate-to-severely active RA as defined by the presence of ≥4 swollen joints (based on 28 joint count) and ≥4 tender joints (based on 28 joint count) at Screening and Day 1.\n* Documentation of ≥1 of the following:\n\n  1. Positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at Screening, OR\n  2. Radiology report documenting bony erosions in hands or feet consistent with RA on previous radiographs\n* Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:\n\n  1. ≥1 csDMARD treatment; AND/OR\n  2. ≤2 classes of bDMARD/tsDMARD treatment (\\>2 classes of bDMARDs and/or tsDMARDs is exclusionary)\n\nFor axial spondyloarthritis:\n\n* Moderate-to-severely active axSpA defined by BOTH of the following at Screening AND Day 1:\n\n  1. BASDAI ≥4, AND\n  2. Back pain ≥4 (from BASDAI Item 2)\n* hsCRP greater than the ULN per the central laboratory at Screening\n* Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:\n\n  1. 2 different NSAIDs given at the maximum tolerated dose for ≥4 weeks or intolerant to or has a contraindication to NSAID therapy; AND/OR\n  2. ≤2 classes of bDMARD (anti-TNF or anti-IL-17)/tsDMARD at an approved dose for ≥12 weeks (\\>2 classes of bDMARDs/tsDMARDs is exclusionary)\n\nFor psoriatic arthritis:\n\n* Screening and Day 1 TJC ≥3 out of 68 and SJC ≥3 out of 66 (dactylitis counts as 1 joint each)\n* ≥1 active plaque psoriasis lesion and/or a documented history of psoriasis\n* Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:\n\n  1. ≥1 NSAID treatment; AND\n  2. ≥1 csDMARD treatment; AND/OR ≤2 classes of bDMARD/tsDMARD treatment (\\>2 classes of bDMARDs and/or tsDMARDs is exclusionary)\n\nExclusion Criteria:\n\n* Inadequate response to \\>2 classes of bDMARDs/tsDMARDs\n* Other autoimmune, rheumatologic, inflammatory diseases or pain-amplification syndromes that might confound the evaluations of efficacy of SPY072","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT","phone":"+1-650-402-3164","email":"info@skyway-rd.com"}],"overallOfficials":[{"name":"SKYWAY-RD Study Director","affiliation":"Spyre Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Site 113","status":"RECRUITING","city":"Avondale","state":"Arizona","zip":"85392","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":33.4356,"lon":-112.3496}},{"facility":"Site 114","status":"RECRUITING","city":"Chula Vista","state":"California","zip":"91910","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":32.64005,"lon":-117.0842}},{"facility":"Site 111","status":"RECRUITING","city":"Covina","state":"California","zip":"91722","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.09001,"lon":-117.89034}},{"facility":"Site 108","status":"RECRUITING","city":"Tujunga","state":"California","zip":"91042","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.25223,"lon":-118.28841}},{"facility":"Site 112","status":"RECRUITING","city":"Upland","state":"California","zip":"91786","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.09751,"lon":-117.64839}},{"facility":"Site 107","status":"RECRUITING","city":"Whittier","state":"California","zip":"90602","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":33.97918,"lon":-118.03284}},{"facility":"Site 109","status":"RECRUITING","city":"Hialeah","state":"Florida","zip":"33016","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Site 106","status":"RECRUITING","city":"Ormond Beach","state":"Florida","zip":"32174","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":29.28581,"lon":-81.05589}},{"facility":"Site 110","status":"RECRUITING","city":"Tampa","state":"Florida","zip":"33614","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Site 104","status":"RECRUITING","city":"Duncansville","state":"Pennsylvania","zip":"16635","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":40.42341,"lon":-78.4339}},{"facility":"Site 105","status":"RECRUITING","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Site 103","status":"RECRUITING","city":"Tomball","state":"Texas","zip":"77375","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"Site 102","status":"RECRUITING","city":"Tomball","state":"Texas","zip":"77377","country":"United States","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"Site 503","status":"RECRUITING","city":"Lovech","state":"Lovech","zip":"5500","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.13227,"lon":24.71763}},{"facility":"Site 502","status":"RECRUITING","city":"Pleven","state":"Pleven","zip":"5803","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.41791,"lon":24.61666}},{"facility":"Site 506","status":"RECRUITING","city":"Plovdiv","state":"Plovdiv","zip":"4000","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.15387,"lon":24.75001}},{"facility":"Site 505","status":"RECRUITING","city":"Plovdiv","state":"Plovdiv","zip":"4003","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.15387,"lon":24.75001}},{"facility":"Site 504","status":"RECRUITING","city":"Varna","state":"Varna","zip":"9000","country":"Bulgaria","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.21912,"lon":27.91024}},{"facility":"Site 706","status":"RECRUITING","city":"Hlučín","state":"Hlučín","zip":"748 01","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":49.89795,"lon":18.19196}},{"facility":"Site 702","status":"RECRUITING","city":"Moravská Ostrava","state":"Ostrava-město","zip":"702 00","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":49.84249,"lon":18.26727}},{"facility":"Site 704","status":"RECRUITING","city":"Pardubice","state":"Pardubický kraj","zip":"530 02","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.04075,"lon":15.77659}},{"facility":"Site 705","status":"RECRUITING","city":"Prague","state":"Praha, Hlavní Mesto","zip":"130 00","country":"Czechia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Site 303","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0102","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 304","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0112","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 301","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0159","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 307","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0172","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 305","status":"RECRUITING","city":"Tbilisi","state":"K'alak'i T'bilisi","zip":"0186","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 308","status":"RECRUITING","city":"Batumi","zip":"6010","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.64077,"lon":41.6306}},{"facility":"Site 302","status":"RECRUITING","city":"Kutaisi","zip":"4600","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.26791,"lon":42.69459}},{"facility":"Site 306","status":"RECRUITING","city":"Tbilisi","zip":"0186","country":"Georgia","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 201","status":"RECRUITING","city":"Chisinau","zip":"MD-2025","country":"Moldova","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 202","status":"RECRUITING","city":"Chisinau","zip":"MD-2025","country":"Moldova","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 401","status":"RECRUITING","city":"Krakow","state":"Lesser Poland Voivodeship","zip":"30-363","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 407","status":"RECRUITING","city":"Nowa Sól","state":"Lubusz Voivodeship","zip":"67-100","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":51.80333,"lon":15.71702}},{"facility":"Site 403","status":"RECRUITING","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-677","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Site 402","status":"RECRUITING","city":"Opole","state":"Opole Voivodeship","zip":"45-819","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.67119,"lon":17.92604}},{"facility":"Site 406","status":"RECRUITING","city":"Gdynia","state":"Pomeranian Voivodeship","zip":"81-384","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Site 405","status":"RECRUITING","city":"Warszawa","state":"Pomeranian Voivodeship","zip":"00-874","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}]},{"facility":"Site 408","status":"RECRUITING","city":"Elblag","state":"Warmian-Masurian Voivodeship","zip":"82-300","country":"Poland","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":54.1522,"lon":19.40884}},{"facility":"Site 602","status":"RECRUITING","city":"A Coruña","state":"A Coruña","zip":"15006","country":"Spain","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Site 604","status":"RECRUITING","city":"Chiclana de la Frontera","state":"Cadiz","zip":"11139","country":"Spain","contacts":[{"name":"SKYWAY-RD Trial Center","role":"CONTACT"}],"geoPoint":{"lat":36.41976,"lon":-6.14367}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D001172","term":"Arthritis, Rheumatoid"},{"id":"D015535","term":"Arthritis, Psoriatic"},{"id":"D000089183","term":"Axial Spondyloarthritis"},{"id":"D012216","term":"Rheumatic Diseases"},{"id":"D003095","term":"Collagen Diseases"}],"ancestors":[{"id":"D001168","term":"Arthritis"},{"id":"D007592","term":"Joint Diseases"},{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D003240","term":"Connective Tissue Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D025242","term":"Spondylarthropathies"},{"id":"D025241","term":"Spondylarthritis"},{"id":"D013166","term":"Spondylitis"},{"id":"D013122","term":"Spinal Diseases"},{"id":"D001847","term":"Bone Diseases"},{"id":"D011565","term":"Psoriasis"},{"id":"D017444","term":"Skin Diseases, Papulosquamous"},{"id":"D012871","term":"Skin Diseases"},{"id":"D000844","term":"Ankylosis"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06873724","orgStudyIdInfo":{"id":"SPY003-207-101"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"SPY003-207 in Healthy Volunteers","officialTitle":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY003-207 in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-03-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-03-07","studyFirstSubmitQcDate":"2025-03-12","studyFirstPostDateStruct":{"date":"2025-03-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-29","lastUpdatePostDateStruct":{"date":"2025-06-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Altasciences Company Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":64,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"SAD Cohorts 1-6 Experimental Arm","type":"EXPERIMENTAL","description":"Participants will receive a single dose of SPY003-207 in a dose escalation format","interventionNames":["Drug: SPY003-207"]},{"label":"SAD Cohorts 1-6 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single dose of placebo","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY003-207","description":"Experimental","armGroupLabels":["SAD Cohorts 1-6 Experimental Arm"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["SAD Cohorts 1-6 Placebo Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment emergent adverse events","description":"Incidence, severity, and causal relationship of TEAEs","timeFrame":"Up to 63 weeks"}],"secondaryOutcomes":[{"measure":"Cmax","description":"Maximum concentration after a single dose","timeFrame":"Up to 63 weeks"},{"measure":"Tmax","description":"Time to reach maximum concentration after a single dose","timeFrame":"Up to 63 weeks"},{"measure":"t1/2","description":"Half life after a single dose","timeFrame":"Up to 63 weeks"},{"measure":"AUC","description":"Area under the curve after a single dose","timeFrame":"Up to 63 weeks"},{"measure":"ADA","description":"Incidence of anti-drug antibody after a single dose","timeFrame":"Up to 63 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men and women\n* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits\n\nExclusion Criteria:\n\n* Participation in more than one cohort\n* Evidence of clinically significant abnormality or disease\n* Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of \\>1 unit of whole blood within 1 month prior to dosing","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Medical Director, Clinical Development","role":"CONTACT","phone":"910-616-0894","email":"Spyre_SPY003-207@spyre.com"}],"overallOfficials":[{"name":"Deanna Nguyen, MD","affiliation":"Spyre Therapeutics","role":"STUDY_CHAIR"}],"locations":[{"facility":"Spyre Site 1","status":"RECRUITING","city":"Montreal","state":"Quebec","zip":"H3P 3P1","country":"Canada","contacts":[{"name":"Claudia Romero de los Reyes","role":"CONTACT","phone":"450-973-3155","phoneExt":"113282","email":"creyes@altasciences.com"}],"geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06448247","orgStudyIdInfo":{"id":"SPY001-101"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of SPY001-001 in Healthy Volunteers","officialTitle":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY001-001 in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2025-02","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-05-05","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-05-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-03","studyFirstSubmitQcDate":"2024-06-03","studyFirstPostDateStruct":{"date":"2024-06-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-02-24","lastUpdatePostDateStruct":{"date":"2025-02-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Altasciences Company Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":96,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"SAD Cohorts 1-5 Experimental Arm","type":"EXPERIMENTAL","description":"Participants will receive a single dose of SPY001-001 in a dose escalation format","interventionNames":["Drug: SPY001-001"]},{"label":"SAD Cohorts 1-5 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single dose of placebo","interventionNames":["Other: Placebo"]},{"label":"MAD Cohorts 1-3 Experimental Arm","type":"EXPERIMENTAL","description":"Participants will receive two doses of SPY001-001 in a dose escalation format","interventionNames":["Drug: SPY001-001"]},{"label":"MAD Cohorts 1-3 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants will receive two doses of placebo","interventionNames":["Other: Placebo"]},{"label":"SAD Cohorts 6-7 Experimental Arm","type":"EXPERIMENTAL","description":"Participants of Japanese descent will receive a single dose of SPY001-001","interventionNames":["Drug: SPY001-001"]},{"label":"SAD Cohorts 6-7 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants of Japanese descent will receive a single dose of placebo","interventionNames":["Other: Placebo"]},{"label":"SAD Cohorts 8-9 Experimental Arm","type":"EXPERIMENTAL","description":"Participants of Chinese descent will receive a single dose of SPY001-001","interventionNames":["Drug: SPY001-001"]},{"label":"SAD Cohorts 8-9 Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants of Chinese descent will receive a single dose of placebo","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY001-001","description":"Experimental","armGroupLabels":["MAD Cohorts 1-3 Experimental Arm","SAD Cohorts 1-5 Experimental Arm","SAD Cohorts 6-7 Experimental Arm","SAD Cohorts 8-9 Experimental Arm"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["MAD Cohorts 1-3 Placebo Arm","SAD Cohorts 1-5 Placebo Arm","SAD Cohorts 6-7 Placebo Arm","SAD Cohorts 8-9 Placebo Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment emergent adverse events","description":"Incidence, severity, and causal relationship of TEAEs","timeFrame":"Up to 64 weeks"}],"secondaryOutcomes":[{"measure":"Cmax","description":"Maximum concentration after single and multiple ascending doses","timeFrame":"Up to 64 weeks"},{"measure":"Tmax","description":"Time to reach maximum concentration after single and multiple ascending doses","timeFrame":"Up to 64 weeks"},{"measure":"t1/2","description":"Half life after single and multiple doses","timeFrame":"Up to 64 weeks"},{"measure":"AUC","description":"Area under the curve after single and multiple ascending doses","timeFrame":"Up to 64 weeks"},{"measure":"ADA","description":"Incidence of anti-drug antibody after single and multiple ascending doses","timeFrame":"Up to 64 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men and women\n* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits\n\nExclusion Criteria:\n\n* Participation in more than one cohort\n* Evidence of clinically significant abnormality or disease\n* Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of \\>1 unit of whole blood within 1 month prior to dosing","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Deanna Nguyen, MD","affiliation":"Spyre Therapeutics","role":"STUDY_CHAIR"}],"locations":[{"facility":"Spyre Site 2","city":"Cypress","state":"California","zip":"90630","country":"United States","geoPoint":{"lat":33.81696,"lon":-118.03729}},{"facility":"Spyre Site 1","city":"Montreal","state":"Quebec","zip":"H3P 3P1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06622070","orgStudyIdInfo":{"id":"SPY002-072-101"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of SPY002-072 in Healthy Volunteers","officialTitle":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-072 in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2024-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-11-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-08-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-09-30","studyFirstSubmitQcDate":"2024-09-30","studyFirstPostDateStruct":{"date":"2024-10-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-11-25","lastUpdatePostDateStruct":{"date":"2024-11-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Altasciences Company Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":56,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"SAD Cohorts, Experimental Arm","type":"EXPERIMENTAL","description":"Participants will receive a single dose of SPY002-072 in a dose escalation format","interventionNames":["Drug: SPY002-072"]},{"label":"SAD Cohorts, Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single dose of placebo","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY002-072","description":"Experimental","armGroupLabels":["SAD Cohorts, Experimental Arm"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["SAD Cohorts, Placebo Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment emergent adverse events","description":"Incidence, severity, and causal relationship of TEAEs","timeFrame":"Up to 40 weeks"}],"secondaryOutcomes":[{"measure":"Cmax","description":"Maximum concentration after single dose","timeFrame":"Up to 40 weeks"},{"measure":"t1/2","description":"Half life after single dose","timeFrame":"Up to 40 weeks"},{"measure":"Tmax","description":"Time to reach maximum concentration after single dose","timeFrame":"Up to 40 weeks"},{"measure":"ADA","description":"Incidence of anti-drug antibody after single dose","timeFrame":"Up to 40 weeks"},{"measure":"AUC","description":"Area under the curve after single dose","timeFrame":"Up to 40 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men and women\n* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits\n\nExclusion Criteria:\n\n* Participation in more than one cohort\n* Evidence of clinically significant abnormality or disease\n* Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Medical Director, Clinical Development","role":"CONTACT","phone":"617-651-5940","email":"Spyre_SPY002-072-101@spyre.com"}],"overallOfficials":[{"name":"Joshua Friedman, MD","affiliation":"Spyre Therapeutics","role":"STUDY_CHAIR"}],"locations":[{"facility":"Spyre Site 2","status":"NOT_YET_RECRUITING","city":"Cypress","state":"California","zip":"90630","country":"United States","contacts":[{"name":"Sammy Armado","role":"CONTACT","phone":"714-252-0700","email":"sarmado@altasciences.com"}],"geoPoint":{"lat":33.81696,"lon":-118.03729}},{"facility":"Spyre Site 1","status":"RECRUITING","city":"Montreal","state":"Quebec","zip":"H3P 3P1","country":"Canada","contacts":[{"name":"Claudia Romero de los Reyes","role":"CONTACT","phone":"450-973-3155 Ext. 113282","email":"creyes@altasciences.com"}],"geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25","removedCountries":["Australia"]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07012395","orgStudyIdInfo":{"id":"SPY123-201"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis","officialTitle":"Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis","acronym":"SKYLINE-UC"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-05-27","studyFirstSubmitQcDate":"2025-06-04","studyFirstPostDateStruct":{"date":"2025-06-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-20","lastUpdatePostDateStruct":{"date":"2026-02-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.","detailedDescription":"This platform study will evaluate the efficacy and safety of investigational treatments, including 3 monotherapies and 3 combination therapies, for moderately to severely active UC in adults. The study will progress in two parts.\n\nPart A is the open-label portion of the study assessing safety and preliminary efficacy of monotherapies.\n\nPart B, which will be open for enrollment after Part A, is the randomized, placebo-controlled portion of the study assessing the safety and efficacy of the 6 interventions (3 monotherapies and 3 combinations) compared to placebo.\n\nIntervention arms will be added to the study over time and may complete at different times."},"conditionsModule":{"conditions":["Ulcerative Colitis","Inflammatory Bowel Diseases","Colitis","Colitis, Ulcerative"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":645,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intervention Specific Appendix - SPY001: Part A","type":"EXPERIMENTAL","description":"Participants will receive open-label dose of SPY001","interventionNames":["Drug: SPY001"]},{"label":"Intervention Specific Appendix - SPY002: Part A","type":"EXPERIMENTAL","description":"Participants will receive open-label dose of SPY002","interventionNames":["Drug: SPY002"]},{"label":"Intervention Specific Appendix - SPY003: Part A","type":"EXPERIMENTAL","description":"Participants will receive open-label dose of SPY003","interventionNames":["Drug: SPY003"]},{"label":"Intervention Specific Appendix - SPY001 Dosing Regimen 1: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 1 of SPY001","interventionNames":["Drug: SPY001"]},{"label":"Intervention Specific Appendix - SPY001 Dosing Regimen 2: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 2 of SPY001","interventionNames":["Drug: SPY001"]},{"label":"Intervention Specific Appendix - SPY002 Dosing Regimen 1: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 1 of SPY002","interventionNames":["Drug: SPY002"]},{"label":"Intervention Specific Appendix - SPY002 Dosing Regimen 2: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 2 of SPY002","interventionNames":["Drug: SPY002"]},{"label":"Intervention Specific Appendix - SPY003 Dosing Regimen 1: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 1 of SPY003","interventionNames":["Drug: SPY003"]},{"label":"Intervention Specific Appendix - SPY003 Dosing Regimen 2: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dosing regimen 2 of SPY003","interventionNames":["Drug: SPY003"]},{"label":"Intervention Specific Appendix - SPY120: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dose of SPY001 and SPY002","interventionNames":["Drug: SPY001","Drug: SPY002"]},{"label":"Intervention Specific Appendix - SPY130: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dose of SPY001 and SPY003","interventionNames":["Drug: SPY001","Drug: SPY003"]},{"label":"Intervention Specific Appendix - SPY230: Part B","type":"EXPERIMENTAL","description":"Participants will receive double-blind dose of SPY002 and SPY003","interventionNames":["Drug: SPY002","Drug: SPY003"]},{"label":"Placebo: Part B","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY001","description":"Experimental","armGroupLabels":["Intervention Specific Appendix - SPY001 Dosing Regimen 1: Part B","Intervention Specific Appendix - SPY001 Dosing Regimen 2: Part B","Intervention Specific Appendix - SPY001: Part A","Intervention Specific Appendix - SPY120: Part B","Intervention Specific Appendix - SPY130: Part B"],"otherNames":["SPY001-001"]},{"type":"DRUG","name":"SPY002","description":"Experimental","armGroupLabels":["Intervention Specific Appendix - SPY002 Dosing Regimen 1: Part B","Intervention Specific Appendix - SPY002 Dosing Regimen 2: Part B","Intervention Specific Appendix - SPY002: Part A","Intervention Specific Appendix - SPY120: Part B","Intervention Specific Appendix - SPY230: Part B"],"otherNames":["SPY002-091"]},{"type":"DRUG","name":"SPY003","description":"Experimental","armGroupLabels":["Intervention Specific Appendix - SPY003 Dosing Regimen 1: Part B","Intervention Specific Appendix - SPY003 Dosing Regimen 2: Part B","Intervention Specific Appendix - SPY003: Part A","Intervention Specific Appendix - SPY130: Part B","Intervention Specific Appendix - SPY230: Part B"],"otherNames":["SPY003-207"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["Placebo: Part B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: Change in Robarts Histopathology Index (RHI)","description":"Change in Robarts Histopathology Index (RHI) from baseline at Week 12 will be assessed. The RHI is used to quantify and assess histological activity of UC, comprising of scores for inflammatory infiltrates, neutrophils, erosions or ulceration. Scores are assigned to each of these features, with a total ranging from 0 (no disease activity) to 33 (most severe disease activity). Higher score indicates more severe disease.","timeFrame":"Week 12"},{"measure":"Part B: Percentage of participants with clinical remission","description":"Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is based on the modified Mayo subscores, which consist of a rectal bleeding subscore (ranging from 0 to 3), stool frequency subscore (ranging from 0 to 3), and endoscopic subscore (ranging from 0 to 3), as assessed by central reading. Higher scores indicate more severe disease.","timeFrame":"Week 12"}],"secondaryOutcomes":[{"measure":"Part A: Percentage of participants with clinical remission","description":"Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is based on the modified Mayo subscores, which consist of a rectal bleeding subscore (ranging from 0 to 3), stool frequency subscore (ranging from 0 to 3), and endoscopic subscore (ranging from 0 to 3), as assessed by central reading. Higher scores indicate more severe disease.","timeFrame":"Week 12"},{"measure":"Part A: Percentage of participants with endoscopic improvement","description":"Percentage of participants with endoscopic improvement at Week 12 will be assessed. Endoscopic improvement based on the Mayo endoscopic subscore (ranging from 0 to 3), as assessed by central reading. Higher score indicates more severe disease.","timeFrame":"Week 12"},{"measure":"Part B: Percentage of participants with endoscopic improvement","description":"Percentage of participants with endoscopic improvement at Week 12 will be assessed. Endoscopic improvement based on the Mayo endoscopic subscore (ranging from 0 to 3), as assessed by central reading. Higher score indicates more severe disease.","timeFrame":"Week 12"},{"measure":"Part B: Percentage of participants with clinical response","description":"Percentage of participants with clinical response at Week 12 will be assessed. Clinical response is based on the modified Mayo Score, which consist of a rectal bleeding subscore (ranging from 0 to 3), stool frequency subscore (ranging from 0 to 3), and endoscopic subscore (ranging from 0 to 3), as assessed by central reading. Higher scores indicate more severe disease.","timeFrame":"Week 12"},{"measure":"Part B: Percentage of participants with histologic improvement","description":"Percentage of participants with histologic improvement at Week 12 will be assessed. Histologic improvement is based on the Geboes score. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. Higher score indicates more severe disease.","timeFrame":"Week 12"},{"measure":"Part B: Percentage of participants achieving histologic endoscopic mucosal improvement (HEMI).","description":"Percentage of participants with HEMI at Week 12 will be assessed. Mucosal improvement is based on the Mayo endoscopic subscore and the Geboes score. The Mayo endoscopic subscore ranges from 0 to 3, as assessed by central reading. Higher score indicates more severe disease. The Geboes histologic index includes 7 histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades from 0 to 5, with each grade of the score divided into 4 or 5 subcategories; the score ranges from 0.0 to 5.4. Higher score indicates more severe disease","timeFrame":"Week 12"},{"measure":"Part B: Percentage of participants with clinical remission","description":"Percentage of participants with clinical remission at Week 48 will be assessed. Clinical remission is based on the modified Mayo subscores, which consist of a rectal bleeding subscore (ranging from 0 to 3), stool frequency subscore (ranging from 0 to 3), and endoscopic subscore (ranging from 0 to 3), as assessed by central reading. Higher scores indicate more severe disease.","timeFrame":"Week 48"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of UC for ≥3 months before Day 1, confirmed by endoscopy and histology either previously or during Screening\n* Active UC with disease extent of ≥15 cm from the anal verge, as confirmed by Screening endoscopy (up to approximately 15% allowed to have only proctitis)\n* Moderately to severely active disease as defined by a modified Mayo score of 5-9, rectal bleeding subscore of ≥1, and Mayo endoscopic subscore ≥2\n\nExclusion Criteria:\n\n* Current diagnosis of Crohn's disease or Inflammatory Bowel Disease (IBD)-Undefined\n* Confirmed or suspected fulminant colitis, toxic megacolon, bowel perforation and/or other conditions that will likely require surgery during induction\n* Failed 4 or more approved or investigational advanced therapy classes","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT","phone":"1-650-402-4238","email":"info@skyline-uc.com"}],"overallOfficials":[{"name":"SKYLINE-UC Study Director","affiliation":"Spyre Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Site 024","status":"RECRUITING","city":"Canoga Park","state":"California","zip":"91304","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.20112,"lon":-118.59814}},{"facility":"Site 012","status":"RECRUITING","city":"Lancaster","state":"California","zip":"93534","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":34.69804,"lon":-118.13674}},{"facility":"Site 033","status":"RECRUITING","city":"Colorado Springs","state":"Colorado","zip":"91304","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Site 007","status":"RECRUITING","city":"Kissimmee","state":"Florida","zip":"34741","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"029","status":"RECRUITING","city":"Miami","state":"Florida","zip":"33165","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Site 006","status":"RECRUITING","city":"Kansas City","state":"Kansas","zip":"66160","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"Site 035","status":"RECRUITING","city":"Marrero","state":"Louisiana","zip":"70072","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":29.89937,"lon":-90.10035}},{"facility":"Site 011","status":"RECRUITING","city":"Glen Burnie","state":"Maryland","zip":"21061","country":"United States","contacts":[{"name":"Skyline-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":39.16261,"lon":-76.62469}},{"facility":"Site 003","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Site 028","status":"RECRUITING","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"040","status":"RECRUITING","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Site 016","status":"RECRUITING","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Site 025","status":"RECRUITING","city":"Providence","state":"Rhode Island","zip":"02904","country":"United States","contacts":[{"name":"SKYLINE- UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Site 017","status":"RECRUITING","city":"Kingsport","state":"Tennessee","zip":"37663","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":36.54843,"lon":-82.56182}},{"facility":"Site 013","status":"RECRUITING","city":"Cedar Park","state":"Texas","zip":"78613","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":30.5052,"lon":-97.82029}},{"facility":"Site 005","status":"RECRUITING","city":"Garland","state":"Texas","zip":"75246","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":32.91262,"lon":-96.63888}},{"facility":"Site 002","status":"RECRUITING","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Site 008","status":"RECRUITING","city":"Southlake","state":"Texas","zip":"76092","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":32.94124,"lon":-97.13418}},{"facility":"Site 009","status":"RECRUITING","city":"Webster","state":"Texas","zip":"77598","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":29.53773,"lon":-95.11826}},{"facility":"Site 019","status":"RECRUITING","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"Site 202","status":"RECRUITING","city":"Heidelberg","zip":"3084","country":"Australia","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"Site 204","status":"RECRUITING","city":"Liverpool","zip":"2170","country":"Australia","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":-33.91938,"lon":150.92588}},{"facility":"Site 207","status":"RECRUITING","city":"Woolloongabba","zip":"4102","country":"Australia","contacts":[{"name":"Skyline--UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Site 463","status":"RECRUITING","city":"Linz","zip":"4021","country":"Austria","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Site 481","status":"RECRUITING","city":"Banja Luka","zip":"78 000","country":"Bosnia and Herzegovina","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":44.77879,"lon":17.20629}},{"facility":"Site 484","status":"RECRUITING","city":"Mostar","zip":"88000","country":"Bosnia and Herzegovina","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.34333,"lon":17.80806}},{"facility":"Site 483","status":"RECRUITING","city":"Sarajevo","zip":"71000","country":"Bosnia and Herzegovina","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":43.84864,"lon":18.35644}},{"facility":"Site 083","status":"RECRUITING","city":"London","state":"Ontario","zip":"G8H 3P7","country":"Canada","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Site 085","status":"RECRUITING","city":"Greater Sudbury","zip":"P3C1X3","country":"Canada","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":46.49,"lon":-80.99001}},{"facility":"Site 086","status":"RECRUITING","city":"London","zip":"N6K 1M6","country":"Canada","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Site 531","status":"RECRUITING","city":"Brno","zip":"615 00","country":"Czechia","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Site 584","status":"RECRUITING","city":"Kutaisi","zip":"4600","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":42.26791,"lon":42.69459}},{"facility":"Site 589","status":"RECRUITING","city":"Marneuli","zip":"3000","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.48758,"lon":44.79845}},{"facility":"Site 581","status":"RECRUITING","city":"Tbilisi","zip":"0102","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 588","status":"RECRUITING","city":"Tbilisi","zip":"0114","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 583","status":"RECRUITING","city":"Tbilisi","zip":"01444","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 586","status":"RECRUITING","city":"Tbilisi","zip":"0144","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 582","status":"RECRUITING","city":"Tbilisi","zip":"0159","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 587","status":"RECRUITING","city":"Tbilisi","zip":"0159","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 590","status":"RECRUITING","city":"Tbilisi","zip":"0178","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 585","status":"RECRUITING","city":"Tbilisi","zip":"0180","country":"Georgia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":41.69143,"lon":44.83412}},{"facility":"Site 604","status":"RECRUITING","city":"Berlin","zip":"14163","country":"Germany","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Site 445","status":"RECRUITING","city":"Beer Yaaqov","zip":"7033001","country":"Israel","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}]},{"facility":"Site 441","status":"RECRUITING","city":"Beersheba","zip":"8410101","country":"Israel","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Site 443","status":"RECRUITING","city":"Haifa","zip":"31048","country":"Israel","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Site 444","status":"RECRUITING","city":"Jerusalem","zip":"9103102","country":"Israel","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Site 446","status":"RECRUITING","city":"Jerusalem","zip":"9112001","country":"Israel","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Site 442","status":"RECRUITING","city":"Nahariya","zip":"2210001","country":"Israel","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":33.00892,"lon":35.09814}},{"facility":"Site 713","status":"RECRUITING","city":"Chisinau","zip":"MD2005","country":"Moldova","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 711","status":"RECRUITING","city":"Chisinau","zip":"MD2025","country":"Moldova","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 712","status":"RECRUITING","city":"Chisinau","zip":"MD2025","country":"Moldova","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 714","status":"RECRUITING","city":"Chisinau","zip":"MD2025","country":"Moldova","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 715","status":"RECRUITING","city":"Chisinau","zip":"MD2068","country":"Moldova","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Site 735","status":"RECRUITING","city":"Katowice","zip":"40-748","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"Site 748","status":"RECRUITING","city":"Krakow","zip":"31-501","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 744","status":"RECRUITING","city":"Sopot","zip":"81-756","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":54.4418,"lon":18.56003}},{"facility":"Site 737","status":"RECRUITING","city":"Szczecin","zip":"71-434","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Site 733","status":"RECRUITING","city":"Szczecin","zip":"71-685","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Site 739","status":"RECRUITING","city":"Warsaw","zip":"00--710","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Site 741","status":"RECRUITING","city":"Warsaw","zip":"02-786","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Site 731","status":"RECRUITING","city":"Warsaw","zip":"04-501","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Site 750","status":"RECRUITING","city":"Warsaw","zip":"57-300","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Site 738","status":"RECRUITING","city":"Wroclaw","zip":"52-416","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Site 734","status":"RECRUITING","city":"Wroclaw","zip":"53-149","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Site 747","status":"RECRUITING","city":"Wroclaw","zip":"53-611","country":"Poland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Trial Site 804","status":"RECRUITING","city":"Belgrade","zip":"11 000","country":"Serbia","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Site 802","status":"RECRUITING","city":"Belgrade","zip":"11000","country":"Serbia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Site 807","status":"RECRUITING","city":"Belgrade","zip":"11000","country":"Serbia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Site 803","status":"RECRUITING","city":"Belgrade","zip":"11080","country":"Serbia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Site 805","status":"RECRUITING","city":"Niš","zip":"18 000","country":"Serbia","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":43.32472,"lon":21.90333}},{"facility":"Site 806","status":"RECRUITING","city":"Užice","zip":"31000","country":"Serbia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":43.85861,"lon":19.84878}},{"facility":"Site 801","status":"RECRUITING","city":"Zrenjanin","zip":"23000","country":"Serbia","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":45.38361,"lon":20.38194}},{"facility":"Site 357","status":"RECRUITING","city":"Busan","zip":"48108","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Site 354","status":"RECRUITING","city":"Daegu","zip":"40404","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Site 358","status":"RECRUITING","city":"Daegu","zip":"42415","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Site 361","status":"RECRUITING","city":"Daegu","zip":"42601","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Site 355","status":"RECRUITING","city":"Daejeon","zip":"34943","country":"South Korea","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":36.34913,"lon":127.38493}},{"facility":"Site 356","status":"RECRUITING","city":"Seoul","zip":"03312","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Site 351","status":"RECRUITING","city":"Seoul","zip":"03722","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Site 352","status":"RECRUITING","city":"Seoul","zip":"06591","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Site 360","status":"RECRUITING","city":"Seoul","zip":"07985","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Site 362","status":"RECRUITING","city":"Seoul","zip":"6351","country":"South Korea","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Site 359","status":"RECRUITING","city":"Suwon","zip":"16247","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Site 353","status":"RECRUITING","city":"Wŏnju","zip":"26426","country":"South Korea","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":37.35139,"lon":127.94528}},{"facility":"Site 834","status":"RECRUITING","city":"Madrid","zip":"28031","country":"Spain","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Site 837","status":"RECRUITING","city":"Madrid","zip":"28222","country":"Spain","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Site 836","status":"RECRUITING","city":"Ourense","zip":"32005","country":"Spain","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":42.33669,"lon":-7.86407}},{"facility":"Site 852","status":"RECRUITING","city":"Basel","zip":"4031","country":"Switzerland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"Site 853","status":"RECRUITING","city":"Bern","zip":"3012","country":"Switzerland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":46.94809,"lon":7.44744}},{"facility":"Site 851","status":"RECRUITING","city":"Sankt Gallen","zip":"9007","country":"Switzerland","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":47.42391,"lon":9.37477}},{"facility":"Site 394","status":"RECRUITING","city":"Changhua","zip":"500","country":"Taiwan","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":24.0692,"lon":120.5512}},{"facility":"Site 392","status":"RECRUITING","city":"Chiayi City","zip":"600","country":"Taiwan","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":23.47917,"lon":120.44889}},{"facility":"Site 396","status":"RECRUITING","city":"Taichung","zip":"404327","country":"Taiwan","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Site 391","status":"RECRUITING","city":"Taipei","zip":"100225","country":"Taiwan","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Site 906","status":"RECRUITING","city":"Ivano-Frankivsk","zip":"76008","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":48.92312,"lon":24.71248}},{"facility":"Site 902","status":"RECRUITING","city":"Kyiv","zip":"02002","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Site 904","status":"RECRUITING","city":"Kyiv","zip":"02091","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Site 905","status":"RECRUITING","city":"Kyiv","zip":"03037","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Site 913","status":"RECRUITING","city":"Kyiv","zip":"04050","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Site 911","status":"RECRUITING","city":"Kyiv","zip":"04107","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Site 903","status":"RECRUITING","city":"Kyiv","zip":"04210","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Site 901","status":"RECRUITING","city":"Lutsk","zip":"43005","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":50.75784,"lon":25.35024}},{"facility":"Site 909","status":"RECRUITING","city":"Lviv","zip":"79010","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Site 912","status":"RECRUITING","city":"Lviv","zip":"79059","country":"Ukraine","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Site 914","status":"RECRUITING","city":"Poltava","zip":"36011","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":49.58925,"lon":34.55367}},{"facility":"Site 908","status":"RECRUITING","city":"Vinnytsia","zip":"21009","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Site 910","status":"RECRUITING","city":"Vinnytsia","zip":"21028","country":"Ukraine","contacts":[{"name":"SKYLINE-UC Trial Center","role":"CONTACT"}],"geoPoint":{"lat":49.2322,"lon":28.46871}},{"facility":"Site 907","status":"RECRUITING","city":"Vinnytsia","zip":"21029","country":"Ukraine","contacts":[{"name":"SKYLINE-UC","role":"CONTACT","phone":"Trial Center"}],"geoPoint":{"lat":49.2322,"lon":28.46871}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003093","term":"Colitis, Ulcerative"},{"id":"D015212","term":"Inflammatory Bowel Diseases"},{"id":"D003092","term":"Colitis"}],"ancestors":[{"id":"D005759","term":"Gastroenteritis"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D003108","term":"Colonic Diseases"},{"id":"D007410","term":"Intestinal Diseases"}]}},"hasResults":false}
]}